# Jacob Vogelstein

> Jacob Vogelstein is a Series A investor at Catalio Capital Management backing Biotechnology. See 11 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management)
- Location: Bethesda, United States
- Total investments: 11
- Last investment: Jun 2026
- Lead investor: 55%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/r-jacob-vogelstein-65821b4

Jacob Vogelstein is a Co-Founder and Managing Partner at Catalio Capital Management, LP. He attended The Johns Hopkins University School of Medicine.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 55% |
| Therapeutics | 5 | 45% |
| Health Care | 4 | 36% |
| Artificial Intelligence | 3 | 27% |
| Medical | 2 | 18% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 45% |
| Series B | 2 | 18% |
| Venture - Series Unknown | 2 | 18% |
| Series D | 1 | 9% |
| Funding Round | 1 | 9% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Flourish | Flourish Labs is a research and development company that combines certified humans, technology, and AI to provide every employee with a dedicated coach. The company builds AI-powered platforms for peer mental health support, focused on making mental health care accessible. | $500M | Series A | Jun 04, 2026 |  |
| Iambic | The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant, a multi-modal transformer model that predicts clinical outcomes from the earliest stages of discovery, and NeuralPLexer, the best-in-class predictor of protein and protein-ligand structures.The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multi-parameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence. | $127.8M |  | Nov 10, 2025 |  |
| Syndeio Biosciences | Syndeio Biosciences is a clinical-stage biotechnology company focused on developing therapies to restore and enhance synaptic health in central nervous system (CNS) disorders. | $90M | Venture - Series Unknown | May 27, 2025 |  |
| Clasp Therapeutics | Clasp Therapeutics offers to reach of immuno-oncology with novel precision medicines that enable the immune system to identify and specifically destroy hard-to-treat tumors bearing common driver mutations, regardless of tumor type. | $150M | Series A | Mar 20, 2024 |  |
| NextPoint Therapeutics | NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. | $42.5M | Series B | Feb 14, 2024 |  |
| Iambic | The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant, a multi-modal transformer model that predicts clinical outcomes from the earliest stages of discovery, and NeuralPLexer, the best-in-class predictor of protein and protein-ligand structures.The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multi-parameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence. | $100M | Series B | Oct 03, 2023 |  |
| Haystack Oncology | Haystack Oncology, an oncology company, uses the most recent circulating tumor DNA detection technology to enhance the diagnosis of minimum residual disease and provide superior therapy decision-making information. | $56M | Series A | Nov 16, 2022 |  |
| Pheast Therapeutics | Pheast Therapeutics is a cancer immunotherapy company focused on developing novel checkpoint therapies to harness the innate immune system in the fight against cancer. It was founded in 2020 and headquartered in Palo Alto, California. | $76M | Series A | Apr 26, 2022 |  |
| Iambic | The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant, a multi-modal transformer model that predicts clinical outcomes from the earliest stages of discovery, and NeuralPLexer, the best-in-class predictor of protein and protein-ligand structures.The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multi-parameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence. | $53M | Series A | Jul 14, 2021 |  |
| Bayesian Health | Bayesian Health is an adaptive AI platform that offers health systems through clinical AI. The company's adaptive AI is intended to integrate with a hospital's EMR, where it provides actionable early detection flags and key insights displayed on the patient list and/or linked with paging, phone, or other escalation pathways to alertthe appropriate clinician. An evidence-based AI/machine learning platform can leverage health systems' significant investment in the EMR as a foundation for patient data and help frontline healthcare providers increase capacity. | $15M | Venture - Series Unknown | Jul 12, 2021 |  |

10 of 11 investments shown.

## Co-investors
- [Nexus Venture Partners](https://shizune.co/investors/profile/nexus-venture-partners) — VC Fund, 4 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 3 deals together
- [Andreessen Horowitz](https://shizune.co/investors/profile/andreessen-horowitz) — VC Fund, 3 deals together
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund, 3 deals together
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 2 deals together
- [Ascenta Capital](https://shizune.co/investors/profile/ascenta-capital) — VC Fund, 2 deals together

## About Catalio Capital Management

VC Fund · Baltimore, United States

Catalio Capital Management is a venture capital firm that invests in breakthrough biomedical technology companies.

5 contacts available at Catalio Capital Management.

| Name | Title | Profile |
| --- | --- | --- |
| Ben Snedeker | Partner and Co-Head Public Equities | https://shizune.co/investors/profile/ben-snedeker |
| George Petrocheilos | Co-Founder & Managing Partner | https://shizune.co/investors/profile/george-petrocheilos |
| Isaac Ro | Partner | https://shizune.co/investors/profile/isaac-ro |
| Jacob Vogelstein | Co-Founder and Managing Partner | https://shizune.co/investors/profile/jacob-vogelstein |
| Kenan Turnacioglu | General Partner | https://shizune.co/investors/profile/kenan-turnacioglu |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Jacob Vogelstein invest in?

Jacob Vogelstein invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series A and Series B stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jacob Vogelstein last invest?

The most recent investment recorded for Jacob Vogelstein closed in Jun 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co